» Articles » PMID: 12894503

Inhibition of Cisplatin-induced ATR Activity and Enhanced Sensitivity to Cisplatin

Overview
Journal Anticancer Res
Specialty Oncology
Date 2003 Aug 5
PMID 12894503
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Ataxia teleangiectasia mutated (ATM) kinase, ATM-Rad3-related (ATR) kinase and DNA-protein kinase (DNA-PK) belong to a subgroup of protein kinases which play a role in the DNA damage response. In this study, cisplatin was shown to increase ATR activity and decrease ATM and DNA-PK activity. Caffeine, a nonspecific inhibitor of ATR, enhanced the cytotoxic effect of cisplatin, modestly decreased the p53 and p21WAF-1 response to cisplatin, and affected the cdc2-p34/cyclin B1 complex by decreasing both cyclin B1 protein accumulation and cdc2-p34 tyrosine 15 phosphorylation. The observed alteration of several potential ATR downstream targets suggests that inhibition of ATR activity may be one of the mechanism by which caffeine regulates sensitivity to cisplatin.

Citing Articles

Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer.

Galsky M, Guan X, Rishipathak D, Rapaport A, Shehata H, Banchereau R Cell Rep Med. 2024; 5(2):101393.

PMID: 38280376 PMC: 10897541. DOI: 10.1016/j.xcrm.2024.101393.


ATR Inhibition in Advanced Urothelial Carcinoma.

Leibrandt R, Tu M, Yu A, Lara P, Parikh M Clin Genitourin Cancer. 2023; 21(2):203-207.

PMID: 36604210 PMC: 10750798. DOI: 10.1016/j.clgc.2022.10.016.


Natural products targeting the ATR-CHK1 signaling pathway in cancer therapy.

Ahmed S, Alam W, Aschner M, Alsharif K, Albrakati A, Saso L Biomed Pharmacother. 2022; 155:113797.

PMID: 36271573 PMC: 9590097. DOI: 10.1016/j.biopha.2022.113797.


ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation.

Gomes L, Rocha C, Martins D, Fiore A, Sarti Kinker G, Bruni-Cardoso A Cell Death Dis. 2019; 10(6):459.

PMID: 31189884 PMC: 6561919. DOI: 10.1038/s41419-019-1689-8.


Targeting the ATR-CHK1 Axis in Cancer Therapy.

Rundle S, Bradbury A, Drew Y, Curtin N Cancers (Basel). 2017; 9(5).

PMID: 28448462 PMC: 5447951. DOI: 10.3390/cancers9050041.